Complete remission of philadelphia chromosome-positive acute myeloid leukemia with imatinib mesylate / 대한내과학회지
Korean Journal of Medicine
;
: 132-137, 2010.
Artigo
em Inglês
| WPRIM
| ID: wpr-86562
ABSTRACT
Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) is a rare disease characterized by a poor prognosis with resistance to standard chemotherapy. We report a patient with Ph+AML with a minor BCR-ABL-positive mRNA transcript who achieved a hematologic, cytogenetic, and major molecular complete response after cytarabine-based chemotherapy followed by imatinib. After more than 6 months of continuous imatinib therapy, the patient is in continuous complete remission. Our results show that imatinib mesylate is effective in treating Ph+AML.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Piperazinas
/
Prognóstico
/
Pirimidinas
/
Benzamidas
/
Cromossomo Filadélfia
/
RNA Mensageiro
/
Leucemia Mieloide Aguda
/
Leucemia
/
Philadelphia
/
Mesilatos
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
País/Região como assunto:
América do Norte
Idioma:
Inglês
Revista:
Korean Journal of Medicine
Ano de publicação:
2010
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS